Literature DB >> 15706975

Immunologic responses to West Nile virus in vaccinated and clinically affected horses.

Ann H Davidson1, Josie L Traub-Dargatz, Racquel M Rodeheaver, Eileen N Ostlund, Douglas D Pedersen, Ron G Moorhead, Joe B Stricklin, Renee D Dewell, Susan D Roach, Rachel E Long, Sara J Albers, Robert J Callan, M D Salman.   

Abstract

OBJECTIVE: To compare neutralizing antibody response between horses vaccinated against West Nile virus (WNV) and horses that survived naturally occurring infection.
DESIGN: Cross-sectional observational study. ANIMALS: 187 horses vaccinated with a killed WNV vaccine and 37 horses with confirmed clinical WNV infection. PROCEDURE: Serum was collected from vaccinated horses prior to and 4 to 6 weeks after completion of an initial vaccination series (2 doses) and 5 to 7 months later. Serum was collected from affected horses 4 to 6 weeks after laboratory diagnosis of infection and 5 to 7 months after the first sample was obtained. The IgM capture ELISA, plaque reduction neutralization test (PRNT), and microtiter virus neutralization test were used.
RESULTS: All affected horses had PRNT titers > or = 1:100 at 4 to 6 weeks after onset of disease, and 90% (18/20) maintained this titer for 5 to 7 months. After the second vaccination, 67% of vaccinated horses had PRNT titers > or = 1:100 and 14% had titers < 1:10. Five to 7 months later, 33% (28/84) of vaccinated horses had PRNT titers > or = 1:100, whereas 29% (24/84) had titers < 1:10. Vaccinated and clinically affected horses' end point titers had decreased by 5 to 7 months after vaccination. CONCLUSIONS AND CLINICAL RELEVANCE: A portion of horses vaccinated against WNV may respond poorly. Vaccination every 6 months may be indicated in certain horses and in areas of high vector activity. Other preventative methods such as mosquito control are warranted to prevent WNV infection in horses.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15706975     DOI: 10.2460/javma.2005.226.240

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  19 in total

1.  Evaluation of Cross-Protection of a Lineage 1 West Nile Virus Inactivated Vaccine against Natural Infections from a Virulent Lineage 2 Strain in Horses, under Field Conditions.

Authors:  Serafeim C Chaintoutis; Nikolaos Diakakis; Maria Papanastassopoulou; Georgios Banos; Chrysostomos I Dovas
Journal:  Clin Vaccine Immunol       Date:  2015-07-15

Review 2.  DNA vaccines for targeting bacterial infections.

Authors:  Mariana Ingolotti; Omkar Kawalekar; Devon J Shedlock; Karuppiah Muthumani; David B Weiner
Journal:  Expert Rev Vaccines       Date:  2010-07       Impact factor: 5.217

3.  Prime-Boost Immunization Eliminates Metastatic Colorectal Cancer by Producing High-Avidity Effector CD8+ T Cells.

Authors:  Bo Xiang; Trevor R Baybutt; Lisa Berman-Booty; Michael S Magee; Scott A Waldman; Vitali Y Alexeev; Adam E Snook
Journal:  J Immunol       Date:  2017-03-24       Impact factor: 5.422

4.  Seroprevalence and Risk Factors for Equine West Nile Virus Infections in Eastern Germany, 2020.

Authors:  Stefanie Ganzenberg; Michael Sieg; Ute Ziegler; Martin Pfeffer; Thomas W Vahlenkamp; Uwe Hörügel; Martin H Groschup; Katharina L Lohmann
Journal:  Viruses       Date:  2022-05-30       Impact factor: 5.818

Review 5.  DNA vaccines: ready for prime time?

Authors:  Michele A Kutzler; David B Weiner
Journal:  Nat Rev Genet       Date:  2008-10       Impact factor: 53.242

6.  Serological evidence of flaviviruses and alphaviruses in livestock and wildlife in Trinidad.

Authors:  Nadin N Thompson; Albert J Auguste; Dane Coombs; Bradley J Blitvich; Christine V F Carrington; Amelia P Travassos da Rosa; Eryu Wang; Dave D Chadee; Michael A Drebot; Robert B Tesh; Scott C Weaver; Abiodun A Adesiyun
Journal:  Vector Borne Zoonotic Dis       Date:  2012-09-18       Impact factor: 2.133

7.  Comparative efficacies of three commercially available vaccines against West Nile Virus (WNV) in a short-duration challenge trial involving an equine WNV encephalitis model.

Authors:  K K Seino; M T Long; E P J Gibbs; R A Bowen; S E Beachboard; P P Humphrey; M A Dixon; M A Bourgeois
Journal:  Clin Vaccine Immunol       Date:  2007-08-08

8.  Modulating APOBEC expression enhances DNA vaccine immunogenicity.

Authors:  Rafael Ribeiro Almeida; Rui André Saraiva Raposo; Fernanda Caroline Coirada; Jamile Ramos da Silva; Luís Carlos de Souza Ferreira; Jorge Kalil; Douglas F Nixon; Edecio Cunha-Neto
Journal:  Immunol Cell Biol       Date:  2015-05-08       Impact factor: 5.126

Review 9.  Microneedles: an innovative platform for gene delivery.

Authors:  Joanne McCaffrey; Ryan F Donnelly; Helen O McCarthy
Journal:  Drug Deliv Transl Res       Date:  2015-08       Impact factor: 5.671

10.  A novel DNA vaccine technology conveying protection against a lethal herpes simplex viral challenge in mice.

Authors:  Julie L Dutton; Bo Li; Wai-Ping Woo; Joshua O Marshak; Yan Xu; Meei-li Huang; Lichun Dong; Ian H Frazer; David M Koelle
Journal:  PLoS One       Date:  2013-10-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.